In good news for healthcare facilities battling MRSA, the U.S. Food and Drug Administration (FDA) recently approved an IV antibiotic to treat dangerous skin infections, such as Methicillin-resistant Staphylococcus aureus, also known as MRSA. Oritavancin (Orbactiv) is designed for people with skin and skin structure infections caused by MRSA and other drug-resistant bacteria.
Orbactiv is used to treat serious or life-threatening infections and has the potential to decrease hospital length of stay and even prevent hospitalizations altogether since it could be administered in a physician's office.
The U.S. Centers for Disease Control and Prevention (CDC) estimates that more than 2 million Americans are infected every year with bacteria that are resistant to antibiotics. MRSA can cause severe problems such as bloodstream infections, pneumonia and surgical site infections. Despite new advances in drug development, drug-resistant infections are a growing concern nationwide, and drug companies are trying everything to slow the epidemic.
The CDC recommends the following safe practices for MRSA Prevention. Doctors, nurses, and other healthcare providers should:
What precautions do you take to prevent the spread of MRSA?